Developer · TEVA · Israel
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is a multinational pharmaceutical company headquartered in Tel Aviv, Israel, that develops, manufactures and markets generic, biosimilar and branded/specialty medicines, including a CNS portfolio. It is dual-listed on the New York Stock Exchange and the Tel Aviv Stock Exchange under the ticker TEVA.
Pipeline (2)
- SchizophreniaFiled (NDA)Active
- Multiple System AtrophyPhase 2Recruiting
Deals & partnerships
- EmrusolminLicensor MODAG GmbH
- Olanzapine extended-release injectable suspension (TEV-'749)Partner Royalty Pharma plcPartner Medincell S.A.
- Nov 13, 2023PartnershipRoyalty Pharma R&D funding agreement to accelerate olanzapine LAI (TEV-'749)Royalty Pharma agreed to provide Teva up to $100 million (with a mutual option to increase to $125 million) to fund ongoing development of olanzapine LAI (TEV-'749). Upon FDA approval, Teva repays the funded amount over five years plus low-to-mid-single-digit royalties on commercialization. Teva retains the lead on development and global commercialization.
- Oct 26, 2021Licensing dealTeva in-licenses anle138b (emrusolmin / TEV-56286) from MODAGMODAG GmbH granted Teva an exclusive worldwide license to develop, manufacture and commercialize anle138b (later named emrusolmin / TEV-56286) and the related compound sery433 for neurodegenerative diseases, with joint development focused on multiple system atrophy (MSA) and Parkinson's disease. MODAG is the originator/licensor; Teva is the licensee and lead developer.
Catalysts · 1 upcoming · 3 reported
- 2H 2027Anticipated
EmrusolminforMultiple System AtrophyTopline data
Anticipated Phase 2 (TOPAS-MSA) topline in multiple system atrophy (primary endpoint: change from baseline in UMSARS at week 48)
Recently reported
- 2026-02-20met
Olanzapine extended-release injectable suspension (TEV-'749)forSchizophreniaRegulatory
FDA accepted Teva's NDA for olanzapine extended-release injectable suspension (TEV-'749) for once-monthly treatment of schizophrenia in adults.
- 2025-05-19met
Olanzapine extended-release injectable suspension (TEV-'749)forSchizophreniaFull results
Completed Phase 3 SOLARIS long-term safety data: no PDSS observed through Week 56, supporting TEV-'749 as the first long-acting olanzapine without a post-injection monitoring requirement.
- 2024-05-29met
Olanzapine extended-release injectable suspension (TEV-'749)forSchizophreniaTopline data
Phase 3 SOLARIS trial: TEV-'749 met primary PANSS endpoint across all three dose groups at Week 8 (all P<0.0001), with key secondary endpoints (CGI-S, PSP) also met.
Recent activity
- Feb 20, 2026ReadoutOlanzapine extended-release injectable suspension (TEV-'749)·SchizophreniametFDA accepted Teva's NDA for olanzapine extended-release injectable suspension (TEV-'749) for once-monthly treatment of schizophrenia in adults.source ↗
- May 19, 2025ReadoutOlanzapine extended-release injectable suspension (TEV-'749)·SchizophreniametCompleted Phase 3 SOLARIS long-term safety data: no PDSS observed through Week 56, supporting TEV-'749 as the first long-acting olanzapine without a post-injection monitoring requirement.source ↗
- Oct 2, 2024Phase changeEmrusolmin·Multiple System AtrophyPhase 2Phase 2 TOPAS-MSA (NCT06568237) initiated; study start date 2024-10-02 (actual) per ClinicalTrials.gov; recruiting in MSA.source ↗
- May 29, 2024ReadoutOlanzapine extended-release injectable suspension (TEV-'749)·SchizophreniametPhase 3 SOLARIS trial: TEV-'749 met primary PANSS endpoint across all three dose groups at Week 8 (all P<0.0001), with key secondary endpoints (CGI-S, PSP) also met.source ↗
- Mar 19, 2024Phase changeOlanzapine extended-release injectable suspension (TEV-'749)·SchizophreniaPhase 3Phase 3 SOLARIS trial (NCT05693935) reached primary completion; TEV-'749 met its primary PANSS endpoint across all three dose groups at Week 8 versus placebo.source ↗
- Oct 1, 2021Phase changeEmrusolmin·Multiple System AtrophyPhase 1MODAG GmbH and Teva announced an exclusive worldwide licensing collaboration to develop anle138b (and related sery433) for MSA and Parkinson's disease (October 2021). Earlier first-in-human Phase 1a (healthy volunteers) and a Phase 1b multiple-ascending-dose study in Parkinson's disease (150-300 mg/day) were conducted by MODAG; exact NCT/dates not re-verified here so summarized without fabrication. changed_at is approximate to the licensing announcement (month-level).source ↗
Trials recruiting · 1 recruiting of 2 sponsored
Showing 0 of 1 recruiting trials.
Competitive landscape
Other companies developing against Teva Pharmaceutical Industries Ltd.'s targets or indications.
- Alkermes plc1 compoundD2Schizophrenia
- LB Pharmaceuticals Inc.1 compoundD2Schizophrenia
- Reviva Pharmaceuticals Holdings, Inc.1 compoundD2Schizophrenia
- Alto Neuroscience, Inc.1 compoundSchizophrenia
- BioXcel Therapeutics, Inc.1 compoundSchizophrenia
- Boehringer Ingelheim International GmbH1 compoundSchizophrenia
- Cerevel Therapeutics Holdings, Inc.1 compoundSchizophrenia
- Engrail Therapeutics, Inc.1 compoundD2
- Intra-Cellular Therapies, Inc.1 compoundSchizophrenia
- MapLight Therapeutics, Inc.1 compoundSchizophrenia
- Merck & Co., Inc.1 compoundSchizophrenia
- Minerva Neurosciences, Inc.1 compoundSchizophrenia
